Haematologic Oncology
Molecular Partners AG focuses on blood cancer research in acute myeloid leukemia and myelodysplastic syndrome, with clinical activity centred on relapsed or refractory disease settings.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Relapsed/Refractory Leukemia
The sponsor’s current clinical work includes evaluation of antileukemic activity in patients with advanced haematologic malignancies.
Leukemia Therapeutics
Its research portfolio includes therapeutic development for AML and MDS/AML, with interest in treatment options for patients whose disease has returned or no longer responds to standard care.
- MDS/AML
- Anti-leukemic activity
- Refractory disease
Clinical investigation is directed toward identifying meaningful activity in difficult-to-treat myeloid malignancies.
Oncology Drug Development
Molecular Partners AG is active in oncology research with a therapeutic emphasis on novel agents for haematological cancers, reflecting a pipeline oriented to treatment innovation in malignant blood disorders.
- Novel oncology agents
- Haematological malignancies
- Therapeutic development
Its clinical programme is centred on advancing candidate therapies for patients with limited treatment options.
Safety and Dose Optimisation in Cancer Care
The sponsor’s clinical research also addresses safety, tolerability, and dose selection in the context of leukaemia treatment, supporting the clinical positioning of investigational oncology therapies.
- Safety and tolerability
- Dose optimisation
- Clinical activity assessment
This area of interest aligns with the development of treatment approaches for patients with advanced myeloid disease.
